<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Blood transfusions represent a main component of supportive care in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>To avoid organ damage caused by transfusion-dependent <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e>, an adequate iron chelation therapy is required </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, a new oral iron <z:chebi fb="0" ids="38161">chelator</z:chebi> <z:chebi fb="0" ids="49005">deferasirox</z:chebi> (<z:chebi fb="0" ids="49005">ICL670</z:chebi>, <z:chebi fb="0" ids="49005">Exjade</z:chebi>) has become available </plain></SENT>
<SENT sid="3" pm="."><plain>A study was conducted to demonstrate the efficacy and tolerability of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> in transfusion-dependent iron-overloaded patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The efficacy of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> was monitored by changes in serum ferritin, bone marrow iron, and liver iron concentration (LIC), as determined by T2*-weighted magnetic resonance imaging </plain></SENT>
<SENT sid="5" pm="."><plain>Twelve patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> of different subtypes (median age 76 years, range 53-91) were enrolled </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> administered in a once-daily dose of 20-30 mg/kg for 12 months was effective in reducing median ferritin concentration from 1,515 microg/L (range 665-6,900) to 413 microg/L (range 105-3,052) </plain></SENT>
<SENT sid="7" pm="."><plain>Within the first 4 weeks of treatment before the continuous decline of ferritin levels, the values markedly rose in eight of 12 patients </plain></SENT>
<SENT sid="8" pm="."><plain>The median LIC declined from 315 to 230 micromol/g (p=0.02) at the end of study, accompanied by a reduction of bone marrow <z:e sem="disease" ids="C0037061" disease_type="Disease or Syndrome" abbrv="">siderosis</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The most common adverse events were mild and transient gastrointestinal disturbances, <z:hpo ids='HP_0000988'>skin rash</z:hpo>, <z:hpo ids='HP_0003680'>nonprogressive</z:hpo> transient increases in serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> and urine beta2-microglobulin, and a temporary reduction of the <z:chebi fb="0" ids="16737">creatinine</z:chebi> clearance </plain></SENT>
<SENT sid="10" pm="."><plain>The renal parameters normalized after end of treatment </plain></SENT>
<SENT sid="11" pm="."><plain>No hematologic toxicities were observed </plain></SENT>
<SENT sid="12" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> proved to be effective in transfusion-dependent <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> by mobilizing iron deposits in liver and at least stabilizing iron stores in bone marrow </plain></SENT>
</text></document>